1. Home
  2. GRFS vs JBTM Comparison

GRFS vs JBTM Comparison

Compare GRFS & JBTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GRFS
  • JBTM
  • Stock Information
  • Founded
  • GRFS 1940
  • JBTM 1994
  • Country
  • GRFS Spain
  • JBTM United States
  • Employees
  • GRFS N/A
  • JBTM N/A
  • Industry
  • GRFS Biotechnology: Pharmaceutical Preparations
  • JBTM
  • Sector
  • GRFS Health Care
  • JBTM
  • Exchange
  • GRFS Nasdaq
  • JBTM Nasdaq
  • Market Cap
  • GRFS 6.6B
  • JBTM 6.9B
  • IPO Year
  • GRFS 2006
  • JBTM N/A
  • Fundamental
  • Price
  • GRFS $9.11
  • JBTM $138.71
  • Analyst Decision
  • GRFS Hold
  • JBTM Strong Buy
  • Analyst Count
  • GRFS 1
  • JBTM 2
  • Target Price
  • GRFS $10.30
  • JBTM $143.00
  • AVG Volume (30 Days)
  • GRFS 592.2K
  • JBTM 598.5K
  • Earning Date
  • GRFS 01-01-0001
  • JBTM 11-03-2025
  • Dividend Yield
  • GRFS 1.58%
  • JBTM 0.29%
  • EPS Growth
  • GRFS 132.60
  • JBTM N/A
  • EPS
  • GRFS 0.53
  • JBTM N/A
  • Revenue
  • GRFS $8,744,226,659.00
  • JBTM $3,257,800,000.00
  • Revenue This Year
  • GRFS $5.46
  • JBTM $120.28
  • Revenue Next Year
  • GRFS $6.69
  • JBTM $4.84
  • P/E Ratio
  • GRFS $22.60
  • JBTM N/A
  • Revenue Growth
  • GRFS 9.32
  • JBTM 92.43
  • 52 Week Low
  • GRFS $6.19
  • JBTM $90.08
  • 52 Week High
  • GRFS $11.14
  • JBTM $148.77
  • Technical
  • Relative Strength Index (RSI)
  • GRFS 36.85
  • JBTM 57.97
  • Support Level
  • GRFS $9.14
  • JBTM $122.35
  • Resistance Level
  • GRFS $9.50
  • JBTM $131.60
  • Average True Range (ATR)
  • GRFS 0.29
  • JBTM 4.08
  • MACD
  • GRFS -0.02
  • JBTM 0.14
  • Stochastic Oscillator
  • GRFS 26.39
  • JBTM 80.36

About GRFS Grifols S.A.

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

About JBTM JBT Marel Corporation

JBT Marel Corp is a technology solutions provider to segments of the food and beverage industry. It designs, produces, and services products and systems for a broad range of end markets, generating roughly one-half of annual revenue from recurring parts, services, rebuilds, and leasing operations.

Share on Social Networks: